On the use of pharmacogenetics in cancer treatment and clinical trials

European Journal of Cancer

Volumn 50, Issue 15, 2014, Pages 2532-2543

  Robert, Jacques ^a   Le Morvan, Valérie ^a   Giovannetti, Elisa ^b   Peters, Godefridus J ^b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anticancer drug response; Anticancer drug toxicity; Biomarkers; Cancer clinical trials; Cancer treatments; Gene polymorphisms; Pharmacogenetics

Indexed keywords

CLINICAL TRIAL (TOPIC); GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; NEOPLASMS; PHARMACOGENETICS; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 84907428044     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.07.013     Document Type: Review

References (36)

1. M.A. Watson, R.K. Stewart, G.B. Smith, T.E. Massey, and D.A. Bell Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution Carcinogenesis 19 1998 275 280
2. R. Saxena, G.L. Shaw, and M.V. Relling Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype Hum Mol Genet 3 1994 923 926
3. C. Kimchi-Sarfaty, J.M. Oh, and I.W. Kim A 'silent' polymorphism in the MDR1 gene changes substrate specificity Science 315 2007 525 528
4. F. Moisan, A. Laroche-Clary, C. Auzanneau, N. Ricard, P. Pourquier, and J. Robert Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity Carcinogenesis 33 2012 962 968
5. A.B. van Kuilenburg, E.W. Muller, and J. Haasjes Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency Clin Cancer Res 7 2001 1149 1153
6. H.G. Xie, A.J. Wood, R.B. Kim, C.M. Stein, and G.R. Wilkinson Genetic variability in CYP3A5 and its possible consequences Pharmacogenomics 5 2004 243 272
7. G.L. Bond, W. Hu, and A. Levine A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect Cancer Res 65 2005 5481 5484
8. F. Innocenti, and M.J. Ratain Irinotecan treatment in cancer patients with UGT1A1 polymorphisms Oncology 17 Suppl. 5 2003 52 55
9. K. Kawakami, D. Salonga, and J.M. Park Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression Clin Cancer Res 7 2001 4096 4101
10. E. Chu, S.M. Copur, and J. Ju Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex Mol Cell Biol 19 1999 1582 1594
11. R. Mauritz, E. Giovannetti, and I.J. Beumer Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer Clin Colorectal Cancer 8 2009 146 154
12. M.J. Linja, and T. Visakorpi Alterations of androgen receptor in prostate cancer J Steroid Biochem Mol Biol 92 2004 255 264
13. C. Sachse, J. Brockmöller, S. Bauer, and I. Roots Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences Am J Hum Genet 60 1997 284 295
14. M. Kagimoto, M. Heim, K. Kagimoto, T. Zeugin, and U.A. Meyer Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes J Biol Chem 265 1990 17209 17214
15. M.M. Regan, B. Leyland-Jones, and M. Bouzyk CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial J Natl Cancer Inst 104 2012 441 451
16. Y. Nakamura, M.J. Ratain, N.J. Cox, H.L. McLeod, D.L. Kroetz, and D.A. Flockhart Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial J Natl Cancer Inst 104 2012 1264
17. A. Laroche-Clary, V. Le Morvan, T. Yamori, and J. Robert Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: studies with in vitro models Mol Cancer Ther 9 2010 3315 3321
18. V. Charasson, D. Hillaire-Buys, I. Solassol, A. Laurand-Quancard, F. Pinguet, and V. Le Morvan Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug sensitivity using the NCI-60 panel as a model Eur J Cancer 45 2009 2391 2401
19. J.C. Barrett, B. Fry, J. Maller, and M.J. Daly Haploview: analysis and visualization of LD and haplotype maps Bioinformatics 21 2005 263 265 http://www.broadinstitute.org/haploview/screenshots
20. J. Ciccolini, C. Mercier, L. Dahan, and N. André Integrating pharmacogenetics into gemcitabine dosing - time for a change? Nat Rev Clin Oncol 8 2011 439 444
21. B.W. Zanke, C.M. Greenwood, and J. Rangrej Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24 Nat Genet 39 2007 989 994
22. T.M. Sissung, B.C. English, D. Venzon, W.D. Figg, and J.F. Deeken Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform Pharmacogenomics 11 2010 89 103
23. C.H. Lin, J.M. Yeakley, T.K. McDaniel, and R. Shen Medium- to high-throughput SNP genotyping using VeraCode microbeads Methods Mol Biol 496 2009 129 142
24. D.L. Hertz, and H.L. McLeod Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology Clin Cancer Res 20 2014 2530 2540
25. Z. Dai, A.C. Papp, D. Wang, H. Hampel, and W. Sadee Genotyping panel for assessing response to cancer chemotherapy BMC Med Genom 1 2008 24
26. Aitouferoukh S, Laurand-Quancard A, Laroche-Clary A, Le Morvan V, Hubert C, Robert J. Conception and validation of a dedicated multiplexed genotyping tool for assessing response to cancer chemotherapy. In: 102nd Annual meeting of the American Association for Cancer Research, Orlando, April 2-5, 2011.
27. V. Le Morvan, S. Litière, and A. Laroche-Clary Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial Pharmacogenomics J 2014 10.1038/tpj.2014.24 [in press]
28. N. Faur, L. Araud, and A. Laroche-Clary The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models Br J Cancer 101 2009 350 356
29. V. Le Morvan, R. Bellott, F. Moisan, S. Mathoulin-Pélissier, J. Bonnet, and J. Robert Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel Pharmacogenomics 7 2006 843 852
30. O.D. Abaan, E.C. Polley, and S.R. Davis The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology Cancer Res 73 2013 4372 4382
31. J. Barretina, G. Caponigro, and N. Stransky The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 483 2012 603 607
32. M.J. Garnett, E.J. Edelman, and S.J. Heidorn Systematic identification of genomic markers of drug sensitivity in cancer cells Nature 483 2012 570 575
33. W. Zhang, and M.E. Dolan Use of cell lines in the investigation of pharmacogenetic loci Curr Pharm Des 15 2009 3782 3795
34. Le Morvan V, Richard E, Bellot R, Pasquies A, Robert J, Lansiaux A. Role of CYP1B1 gene polymorphisms in anticancer drug cytotoxicity as studied on isogenic cell lines. In: 103rd Annual meeting of the American Association for Cancer Research, Chicago, April 1-4, 2012.
35. W.G. Hou, W.B. Ai, and X.G. Bai Genetic variation in the EGFR gene and the risk of glioma in a Chinese Han population PLoS One 7 2012 e37531
36. T.K. Rice, N.J. Schork, and D.C. Rao Methods for handling multiple testing Adv Genet 60 2008 293 308